Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “pEYS606 is a DNA plasmid solution administered by electrotransfection into the ciliary muscle”In the company’s words, NCT03308045 on ClinicalTrials.gov
- Tested for
- Non-infectious Uveitis
- Main trialPhase 1/2
- “Primary objective: safety and tolerability Secondary objectives: additional indicators of long term safety and indicators of clinical activity Exploratory objectives: to characterize EYS606 biodistribution, immunogenicity and biomarkers”In the company’s words, NCT03308045 on ClinicalTrials.gov
Other drugs for Non-infectious Uveitis
- ApremilastAmgen · Phase 3
- BaricitinibEli Lilly · Phase 3
- Brepocitinib QDPriovant Therapeutics, Inc. · Phase 3
- Hemay005Ganzhou Hemay Pharmaceutical Co., Ltd · Phase 3
- FXS5626Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · Phase 2
- GenakumabChangchun GeneScience Pharmaceutical Co., Ltd. · Phase 2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Completed | 1 Jun 2021 | Evaluation of EYS606 in Patients With Non-infectious Posterior, Intermediate or Panuveitis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026